Loading…
Champions Oncology, Inc. is projected to rise to $6.02 by 2027, a +12% move from its current price of $5.36. CSBR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $5.21 | $5.36 | $5.52 | +0.04% |
| Aug 5 | $5.15 | $5.36 | $5.59 | +0.08% |
| Aug 6 | $5.10 | $5.37 | $5.64 | +0.12% |
| Aug 7 | $5.07 | $5.37 | $5.69 | +0.16% |
| Aug 8 | $5.03 | $5.37 | $5.73 | +0.20% |
| Aug 9 | $5.01 | $5.37 | $5.77 | +0.24% |
| Aug 10 | $4.98 | $5.38 | $5.80 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.98 | $5.38 | $5.80 | +0.28% |
| Week 2 | $4.84 | $5.39 | $6.01 | +0.57% |
| Week 3 | $4.73 | $5.41 | $6.17 | +0.85% |
| Week 4 | $4.65 | $5.42 | $6.32 | +1.14% |
| Week 5 | $4.58 | $5.44 | $6.45 | +1.43% |
| Week 6 | $4.52 | $5.45 | $6.58 | +1.71% |
| Week 7 | $4.47 | $5.47 | $6.69 | +2.00% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Champions Oncology, Inc. (CSBR) operates in the healthcare sector as a technology-enabled research company serving the United States. Through its Tumorgraft technology platform, the company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice.
It also offers translational oncology solutions that utilize its technology platform to provide research services that assist in the drug development process for pharmaceutical and biotechnology companies.
In addition, Champions Oncology markets Lumin Bioinformatics, an oncology data-driven software program containing information drawn from research services and clinical studies. The company markets its products through the internet and a sales force to pharmaceutical and biotechnology companies. It was formerly known as Champions Biotechnology, Inc.
and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Champions Oncology, Inc. trades under the CSBR symbol in the healthcare space. The current price is $5.26 and the company's market capitalization is $73.08M, with a market rank of 4105.
The stock’s near-term technical backdrop shows bearish momentum, with a 14-day RSI of 30 and key moving averages around the current price (SMA50 at $6.00 and SMA200 at $6.30).
The stock sits on support at $5.26 and faces resistance at $6.82. The 30-day price range spans from $4.33 to $6.39, and annualized volatility stands at 60%. These technicals suggest limited upside in the short run unless price action firms above resistance or momentum shifts.
A major floor 18.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.9% away) — a key level to hold.
The nearest ceiling, 23.7% above — a clean break opens room to run.
A major ceiling 32.8% above — clearing it would confirm fresh momentum.
Key CSBR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CSBR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.53 | Sell | $5.51 | Sell |
| MA 10 | $5.81 | Sell | $5.68 | Sell |
| MA 20 | $5.84 | Sell | $5.82 | Sell |
| MA 50 | $5.98 | Sell | $5.94 | Sell |
| MA 100 | $5.97 | Sell | $6.04 | Sell |
| MA 200 | $6.29 | Sell | $6.25 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.73 | Neutral |
| Stoch RSI (14) | 16.32 | Buy |
| CCI (20) | -154.94 | Sell |
| Williams %R (14) | -88.51 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | -7.27 | Sell |
| Bollinger %B (20,2) | 0.04 | Neutral |
| Stochastic %K (14) | 11.49 | Buy |
| TRIX (15) | -0.17 | Sell |
| Awesome (5,34) | -0.51 | Sell |
| Ultimate (7,14,28) | 27.19 | Buy |
| Momentum (10) | -0.77 | Sell |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 5.20 | Buy |
| ADX (14) | 13.63 | Neutral |
| ATR (14) | 0.15 | Info |
The 30-day technical picture is bearish, with RSI at 30 signaling soft momentum. Price is approaching the immediate support of $5.26 while facing resistance near $6.82, framing a narrow near-term trading range.
The observed 30-day range is $4.33 to $6.39, underscoring the stock’s limited maneuvering within a relatively tight band. Annualized volatility is elevated at 60%, which implies substantial swings could resume if price breaks out from the current range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.26 | $5.36 | $6.86 | 0% | Neutral | |
| $4.78 | $6.02 | $8.04 | +12% | Neutral | |
| $4.37 | $5.67 | $7.88 | +6% | Neutral | |
| $4.90 | $6.53 | $9.35 | +22% | Bullish | |
| $6.05 | $8.24 | $12.11 | +54% | Bullish | |
| $6.49 | $9.01 | $13.54 | +68% | Bullish | |
| $7.06 | $9.99 | $15.31 | +86% | Bullish | |
| $7.24 | $10.43 | $16.28 | +95% | Bullish | |
| $7.15 | $10.47 | $16.62 | +95% | Bullish | |
| $7.46 | $11.09 | $17.88 | +107% | Bullish | |
| $10.52 | $16.82 | $28.92 | +214% | Bullish | |
| $19.12 | $34.66 | $65.44 | +547% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $5.26 | $5.36 | $6.37 | +0.00% |
| September 2026 | $4.63 | $5.48 | $6.69 | +2.32% |
| October 2026 | $4.66 | $5.56 | $6.86 | +1.41% |
| November 2026 | $4.53 | $5.44 | $6.77 | -2.22% |
| December 2026 | $4.53 | $5.47 | $6.86 | +0.53% |
Click any year to see its month-by-month CSBR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Champions Oncology, Inc.'s 2026 outlook centres on $5.36, within a $5.26 to $6.86 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CSBR could reach as high as $8.04, with a base case around $6.02 and support toward $4.78 — roughly +12% from $5.36. Price action looks broadly range-bound.
Expect CSBR to range from $4.37 to $7.88 through 2028. The $5.67 average target implies a +6% move from current prices. That is -6% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The CSBR price prediction for 2029 points to an average of $6.53 (low $4.90, high $9.35) — a potential gain of +22% on today's $5.36. Momentum favours further upside here.
In 2030, CSBR is projected to trade between $6.05 and $12.11, averaging $8.24 — a potential gain of +54% from today's $5.36. That is up +26% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Champions Oncology, Inc.'s 2031 outlook centres on $9.01, within a $6.49 to $13.54 range. That is up +9% on the projected 2030 average. That marks a +68% change versus current levels. Momentum favours further upside here.
By 2032, CSBR could reach as high as $15.31, with a base case around $9.99 and support toward $7.06 — roughly +86% from $5.36. Buyers look set to stay in control over this stretch.
Expect CSBR to range from $7.24 to $16.28 through 2033. The $10.43 average target implies a +95% move from current prices. That is up +4% on the projected 2032 average. Momentum favours further upside here.
The CSBR price prediction for 2034 points to an average of $10.47 (low $7.15, high $16.62) — a potential gain of +95% on today's $5.36. Buyers look set to stay in control over this stretch.
In 2035, CSBR is projected to trade between $7.46 and $17.88, averaging $11.09 — a potential gain of +107% from today's $5.36. That is up +6% on the projected 2034 average. Momentum favours further upside here.
Champions Oncology, Inc.'s 2040 outlook centres on $16.82, within a $10.52 to $28.92 range. That is up +52% on the projected 2035 average. That marks a +214% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CSBR could reach as high as $65.44, with a base case around $34.66 and support toward $19.12 — roughly +547% from $5.36. Momentum favours further upside here.
Investing $1,000 in CSBR today (≈ 186.567164 CSBR) could be worth
$6,467.13
+$5,467.13 (+547%) by 2050 · US Dollar
Based on the average projected CSBR price of $34.66 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CSBRwould be worth at today's price.
$1,000 invested in CSBR on Jul 31, 2025 (≈ 158.227844 CSBR) would be worth
$848.1
-$151.9 (-15.2%) today · 0.85× · US Dollar
Based on a CSBR entry price of $6.32 vs. today's $5.36.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.13 | $874.39 | -12.6% |
| 1 month ago | $6.05 | $885.95 | -11.4% |
| 3 months ago | $5.99 | $894.82 | -10.5% |
| 6 months ago | $7.13 | $751.75 | -24.8% |
| 1 year ago | $6.32 | $848.1 | -15.2% |
| All time (5.0y) ago | $10.49 | $510.96 | -48.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CSBR forecast.
Our base-case forecast reaches $11.00 around 2035.
Implied market cap at $11.00: $152.83M
The multi-year forecast shows a shift from neutral to bullish sentiment over time. For 2026, the min and avg are both $5.26 with a max of $6.76 and a 0% ROI, reflecting a neutral outlook. In 2027, the avg rises to $5.90 with a max of $7.90 and a 12.1% ROI, maintaining a neutral stance.
From 2029 onward, the forecast turns more clearly bullish, with the 2030 avg at $8.09 and a max of $11.94, yielding a 53.7% ROI. By 2031 the avg is $8.80 and the max $13.29 (67.2% ROI), climbing further to 2032 with an avg of $9.81 and max of $15.13 (86.6% ROI) and 2033 where the avg is $10.22 and max $16.05 (94.3% ROI).
The upward trajectory continues through 2034–2035, 2040, and 2050: 2034 avg $10.19, max $16.27 (93.7% ROI); 2035 avg $10.86, max $17.61 (106.4% ROI); 2040 avg $16.39, max $28.38 (211.5% ROI); and 2050 avg $34.01, max $64.76 (546.6% ROI).
Overall, the forecast paints a rising long-term path with substantial upside potential by mid-century, but it also carries uncertainty and the risk of near-term headwinds given the current bearish technical backdrop.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $8.09 with a maximum of $11.94 and a minimum of $5.92, accompanied by a 53.7% ROI and a bullish sentiment.
The long-range outlook turns bullish from 2029 onward, with the average price rising to $8.09 in 2030 and a 53.7% ROI, then progressing to higher averages and a 546.6% ROI by 2050. However, near-term conditions are bearish, and do note that forecasts are not guarantees.
Yes. The 2030 max is $11.94 and the 2031 max is $13.29, indicating that reaching or exceeding $10 by 2030–2031 is within the forecasted upside.
The 30-day price range is $4.33 to $6.39.
The current price is $5.26 and the market cap is $73.08M.
Champions Oncology, Inc. Community Discussion
0Share your Champions Oncology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.